One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer

被引:25
作者
Rizzo, Andrea [1 ]
Napoli, Alessandra [1 ]
Roggiani, Francesca [1 ]
Tomassetti, Antonella [1 ]
Bagnoli, Marina [1 ]
Mezzanzanica, Delia [1 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori, Unit Mol Therapies, Dept Res, Via Amadeo 42, I-20133 Milan, Italy
关键词
one-carbon metabolism; epithelial ovarian cancer; choline metabolism; folate; folate receptor alpha; CHOLINE-KINASE-ALPHA; FOLATE-BINDING-PROTEIN; PLATINUM-RESISTANT; DNA METHYLATION; PHOSPHOLIPID-METABOLISM; IN-VITRO; MAINTENANCE THERAPY; MONOCLONAL-ANTIBODY; CARCINOMA PATIENTS; LIPID-METABOLISM;
D O I
10.3390/ijms19072092
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Metabolism is deeply involved in cell behavior and homeostasis maintenance, with metabolites acting as molecular intermediates to modulate cellular functions. In particular, one-carbon metabolism is a key biochemical pathway necessary to provide carbon units required for critical processes, including nucleotide biosynthesis, epigenetic methylation, and cell redox-status regulation. It is, therefore, not surprising that alterations in this pathway may acquire fundamental importance in cancer onset and progression. Two of the major actors in one-carbon metabolism, folate and choline, play a key role in the pathobiology of epithelial ovarian cancer (EOC), the deadliest gynecological malignancy. EOC is characterized by a cholinic phenotype sustained via increased activity of choline kinase alpha, and via membrane overexpression of the alpha isoform of the folate receptor (FR alpha), both of which are known to contribute to generating regulatory signals that support EOC cell aggressiveness and proliferation. Here, we describe in detail the main biological processes associated with one-carbon metabolism, and the current knowledge about its role in EOC. Moreover, since the cholinic phenotype and FR alpha overexpression are unique properties of tumor cells, but not of normal cells, they can be considered attractive targets for the development of therapeutic approaches.
引用
收藏
页数:16
相关论文
共 140 条
  • [1] Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
    Armstrong, Deborah K.
    White, Allen J.
    Weil, Susan C.
    Phillips, Martin
    Coleman, Robert L.
    [J]. GYNECOLOGIC ONCOLOGY, 2013, 129 (03) : 452 - 458
  • [2] The folate receptor as a rational therapeutic target for personalized cancer treatment
    Assaraf, Yehuda G.
    Leamon, Christopher P.
    Reddy, Joseph A.
    [J]. DRUG RESISTANCE UPDATES, 2014, 17 (4-6) : 89 - 95
  • [3] Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to α-folate receptor overexpression
    Bagnoli, M
    Tomassetti, A
    Figini, M
    Flati, S
    Dolo, V
    Canevari, S
    Miotti, S
    [J]. ONCOGENE, 2000, 19 (41) : 4754 - 4763
  • [4] Bagnoli M., 2016, FRONTIERS ONCOLOGY, P6
  • [5] The impact of diabetes on survival in women with ovarian cancer
    Bakhru, Arvind
    Buckanovich, Ronald J.
    Griggs, Jennifer J.
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : 106 - 111
  • [6] Epigenetic Changes in Ovarian Cancer
    Balch, Curt
    Fang, Fang
    Matei, Daniela E.
    Huang, Tim H. -M.
    Nephew, Kenneth P.
    [J]. ENDOCRINOLOGY, 2009, 150 (09) : 4003 - 4011
  • [7] Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological Impact
    Black, Joshua C.
    Van Rechem, Capucine
    Whetstine, Johnathan R.
    [J]. MOLECULAR CELL, 2012, 48 (04) : 491 - 507
  • [8] BOTTERO F, 1993, CANCER RES, V53, P5791
  • [9] The α folate receptor is highly activated in malignant pleural mesothelioma
    Bueno, R
    Appasani, K
    Mercer, H
    Lester, S
    Sugarbaker, D
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 121 (02) : 225 - 233
  • [10] CAMPBELL IG, 1991, CANCER RES, V51, P5329